Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745064 | 0.96 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL20745058 | 0.78 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL16816242 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL16815686 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL16815848 | 0.76 | L3MBTL1 (0.41) | SMN1; SMN2KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL18342624 | 0.76 | KMT2A (0.44) | SMN1; SMN2KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL20745566 | 0.75 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2ARAB9AMAPTL3MBTL1 | |
| SCHEMBL22262748 | 0.73 | MAPT (0.45) | SMN1; SMN2KMT2AMAPTL3MBTL1MEN1 | |
| SCHEMBL20745390 | 0.73 | MAPT (0.45) | SMN1; SMN2KMT2AMAPTL3MBTL1MEN1 | |
| SCHEMBL13554406 | 0.71 | CYP3A4 (0.50) | MAPTKDM4ECHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709334-B | Novel amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-04-13 | — | — | CN | disclosed |
| US-10457687-B2 | Aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-10-29 | — | — | US | disclosed |
| US-20190031675-A1 | AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-01-31 | — | — | US | disclosed |
| EP-3313850-B1 | NEW AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031675-A1 | AMINOACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, ARG2, ANXA5 | SMN1; SMN2 849/4885KMT2A 3663/4885RAB9A 305/4885 |
| US-10457687-B2 | Aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, ARG2, ANXA5 | SMN1; SMN2 849/4885KMT2A 3663/4885RAB9A 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.